Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT01188304
An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 250
- Registration Number
- NCT01187381
- Locations
- 🇷🇴
Cluj Clinical County Hospital; Oncology Dept, Cluj-Napoca, Romania
A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT01185860
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT01185847
An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 719
- Registration Number
- NCT01185522
A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 81
- Registration Number
- NCT01185873
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
- First Posted Date
- 2010-08-18
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 315
- Registration Number
- NCT01183858
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT01183598
A Study of RO4917838 With Rosuvastatin in Healthy Volunteers
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01183585
A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic, Healthy Volunteer
- Interventions
- Drug: PlaceboDrug: RO5303253
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 82
- Registration Number
- NCT01181024
© Copyright 2025. All Rights Reserved by MedPath